← Back to Search

Physiology Assessment

FFRangio for Coronary Artery Disease (ALL-RISE Trial)

N/A

Recruiting

Led By Allen Jeremias, MD, MSc

Research Sponsored by CathWorks Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

ALL-RISE Trial Summary

This trial tests if a new approach to treating coronary artery disease is as good as the current one.

Who is the study for?

This trial is for adults over 18 with certain types of chest pain (CCS or NSTEACS) who have a blockage in their heart's arteries that's suitable for special tests to measure blood flow. They can't join if they're not right for these tests.Check my eligibility

What is being tested?

The study is looking at whether using FFRangio, a new way to assess blood flow in the coronary arteries during procedures, works as well as the standard pressure wire-guided method used during angioplasty.See study design

What are the potential side effects?

Possible side effects may include discomfort at the catheter insertion site, bleeding, allergic reactions to contrast dye used in imaging, and rare complications related to heart catheterization like artery damage.

ALL-RISE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

MACE

Secondary outcome measures

All-Cause Mortality

Bleeding

Contrast Dose

+14 more

ALL-RISE Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: FFRangioExperimental Treatment1 Intervention

FFRangio guided revascularization

Group II: Pressure wireActive Control1 Intervention

Pressure wire-based guided revascularization (FFR or NHPR)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Cardiovascular Research Foundation, New YorkOTHER

24 Previous Clinical Trials

25,106 Total Patients Enrolled

CathWorks Ltd.Lead Sponsor

3 Previous Clinical Trials

616 Total Patients Enrolled

Allen Jeremias, MD, MScPrincipal InvestigatorSt. Francis Hospital & Heart Center

Media Library

FFRangio (Physiology Assessment) Clinical Trial Eligibility Overview. Trial Name: NCT05893498 — N/A

Percutaneous Coronary Intervention Research Study Groups: FFRangio, Pressure wire

Percutaneous Coronary Intervention Clinical Trial 2023: FFRangio Highlights & Side Effects. Trial Name: NCT05893498 — N/A

FFRangio (Physiology Assessment) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05893498 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can any new participants still join this scientific trial?

"According to the details available on clinicaltrials.gov, this trial is not presently recruiting participants. First posted in June of 2023 and last updated at the end of May, there are currently 49 other medical studies actively searching for volunteers."

Answered by AI

At how many venues is this experiment currently taking place?

"The medical study is currently running in 6 different centres, including Palo Alto - VA (Palo Alto), Stanford University (Detroit) and Ascension St. John Hospital (Allentown). Additionally, there are 3 other sites participating in the research."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

2023. "Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05893498.